Literature DB >> 31441002

Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.

Cheng-Lin Zhu1, Qiang Huang2.   

Abstract

BACKGROUND: The Suvar, Enhancer of zeste, and Trithorax (SET), myeloid-Nervy-DEAF-1 (MYND) domain-containing protein 3 (SMYD3), was reported to be upregulated in various tumors. However, its role in pancreatic cancer progression remains unclear. AIMS: To explore the role of SMYD3 in the pancreatic cancer.
METHODS: The expressions of SMYD3, caspase-3, and matrix metallopeptidase-2 (MMP-2) were detected in pancreatic cancer and non-tumor tissues by immunohistochemistry. The CCK-8 and transwell assays were performed to test proliferation, migration, and invasion ability in short hairpin RNA (shRNA-SMYD3) pancreatic cancer cell line SW1190. RT-PCR and Western blot were used to detect the expressions of SMYD3, caspase-3, and MMP-2 in SW1990 cell line and shRNA-SMYD3 SW1990 cell line.
RESULTS: The expressions of SMYD3, caspase-3, and MMP-2 were upregulated in pancreatic cancer. The SMYD3 was positively associated with caspase-3 and MMP-2 expressions in pancreatic cancer tissues. SMYD3, TNM stages, histological differentiation, and lymph node metastasis were identified as an independent prognostic factor. Moreover, interfered SMYD3 expression in SW1990 cell line significantly reduced the cell proliferation, migration, and invasion. RT-PCR and Western blot showed the expression of MMP-2 decreased in shRNA-SMYD3 SW1990 cell line, but no significant change was observed in the caspase-3 expression.
CONCLUSIONS: The overexpression of SMYD3 promoted proliferation, migration, and invasion of pancreatic cancer, and SMYD3 may affect the pancreatic cancer progression by regulating MMP-2 rather than caspase-3.

Entities:  

Keywords:  Caspase-3; MMP-2; Pancreatic neoplasms; SMYD3

Mesh:

Substances:

Year:  2019        PMID: 31441002     DOI: 10.1007/s10620-019-05797-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Intronic RNAs mediate EZH2 regulation of epigenetic targets.

Authors:  Sònia Guil; Marta Soler; Anna Portela; Jordi Carrère; Elena Fonalleras; Antonio Gómez; Alberto Villanueva; Manel Esteller
Journal:  Nat Struct Mol Biol       Date:  2012-06-03       Impact factor: 15.369

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.

Authors:  Xiao Fei; Yun Ma; Xiaowei Liu; Zhixin Meng
Journal:  Tohoku J Exp Med       Date:  2017-11       Impact factor: 1.848

4.  High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas.

Authors:  A Nakagawara; Y Nakamura; H Ikeda; T Hiwasa; K Kuida; M S Su; H Zhao; A Cnaan; S Sakiyama
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

5.  Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer.

Authors:  Honggen Liu; Yong Liu; Fanming Kong; Wen Xin; Xiaojiang Li; Han Liang; Yingjie Jia
Journal:  J Am Coll Surg       Date:  2015-03-04       Impact factor: 6.113

6.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.

Authors:  Ryuji Hamamoto; Yoichi Furukawa; Masashi Morita; Yuko Iimura; Fabio Pittella Silva; Meihua Li; Ryuichiro Yagyu; Yusuke Nakamura
Journal:  Nat Cell Biol       Date:  2004-07-04       Impact factor: 28.824

7.  Metalloproteinase 2 and 9 activity in the development of pancreatic cancer.

Authors:  Marek Durlik; Katarzyna Gardian
Journal:  Pol Przegl Chir       Date:  2012-08

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

9.  Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.

Authors:  M Tewari; L T Quan; K O'Rourke; S Desnoyers; Z Zeng; D R Beidler; G G Poirier; G S Salvesen; V M Dixit
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.

Authors:  Michalis E Sarris; Panagiotis Moulos; Anna Haroniti; Antonis Giakountis; Iannis Talianidis
Journal:  Cancer Cell       Date:  2016-02-18       Impact factor: 31.743

View more
  9 in total

1.  Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.

Authors:  Yang Wang; ShanShan Wang; Yang Che; DeXi Chen; YaLi Liu; Ying Shi
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

2.  Role of germline variants in the metastasis of breast carcinomas.

Authors:  Ángela Santonja; Aurelio A Moya-García; Nuria Ribelles; Begoña Jiménez-Rodríguez; Bella Pajares; Cristina E Fernández-De Sousa; Elísabeth Pérez-Ruiz; María Del Monte-Millán; Manuel Ruiz-Borrego; Juan de la Haba; Pedro Sánchez-Rovira; Atocha Romero; Anna González-Neira; Ana Lluch; Emilio Alba
Journal:  Oncotarget       Date:  2022-06-30

3.  Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.

Authors:  Pushkar Chandra; Ruhi Dixit; Arvind Pratap; Suman Mishra; Rajnikant Mishra; Vijay Kumar Shukla
Journal:  Indian J Surg Oncol       Date:  2020-07-11

Review 4.  Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?

Authors:  Etienne J Slapak; JanWillem Duitman; Cansu Tekin; Maarten F Bijlsma; C Arnold Spek
Journal:  Biology (Basel)       Date:  2020-04-18

Review 5.  SMYD3: a regulator of epigenetic and signaling pathways in cancer.

Authors:  Benjamin J Bernard; Nupur Nigam; Kyunghee Burkitt; Vassiliki Saloura
Journal:  Clin Epigenetics       Date:  2021-02-26       Impact factor: 6.551

Review 6.  An Overview of Epigenetic Methylation in Pancreatic Cancer Progression.

Authors:  Yuhao Zhao; Mao Yang; Shijia Wang; Sk Jahir Abbas; Junzhe Zhang; Yongsheng Li; Rong Shao; Yingbin Liu
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

7.  Identifying novel SMYD3 interactors on the trail of cancer hallmarks.

Authors:  Candida Fasano; Martina Lepore Signorile; Katia De Marco; Giovanna Forte; Paola Sanese; Valentina Grossi; Cristiano Simone
Journal:  Comput Struct Biotechnol J       Date:  2022-04-11       Impact factor: 6.155

8.  SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.

Authors:  Fu-Ren Yue; Zhi-Bin Wei; Rui-Zhen Yan; Qiu-Hong Guo; Bing Liu; Jing-Hui Zhang; Zheng Li
Journal:  Exp Ther Med       Date:  2020-08-25       Impact factor: 2.447

9.  The clinical significance of microRNA-409 in pancreatic carcinoma and associated tumor cellular functions.

Authors:  Kui Long; Qingbin Zeng; Wenzhi Dong
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.